-
Mashup Score: 2Isatuximab Plus VRd Approved by FDA for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma - 4 month(s) ago
On September 20, the U.S. Food and Drug Administration (FDA) approved the monoclonal antibody isatuximab-irfc (Sarclisa) in combination with bortezomib, lenalidomide, and dexamethasone for adults with…
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 5Delays in Oral Antimyeloma Treatment Initiation: Role of Social Determinants of Health - 4 month(s) ago
A retrospective cohort study revealed discrepancies between the timing of the initiation of any treatment and the fill of prescriptions for oral antimyeloma medications in patients with multiple myelo…
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Delays in Oral Antimyeloma Treatment Initiation: Role of Social Determinants of Health https://t.co/jBKIVe8WGB #mmsm #multiplemyeloma #hematology
-
-
Mashup Score: 3What Is the Better Target for Bispecific Antibodies in Multiple Myeloma: BCMA or GPRC5D? - 4 month(s) ago
For relapsed or refractory multiple myeloma, there are three available bispecific antibodies—two that target B-cell maturation antigen (BCMA) and one that targets G protein–coupled receptor class C gr…
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
What Is the Better Target for Bispecific Antibodies in Multiple Myeloma: BCMA or GPRC5D? https://t.co/NjMqPWSaRF #mmsm #MultipleMyeloma #hematology
-
-
Mashup Score: 4Novel Insights Into Multiple Myeloma Progression - 5 month(s) ago
In the prospective, longitudinal, observational clinical CoMMpass study, researchers analyzed data from 1,143 patients with newly diagnosed, previously untreated multiple myeloma. To understand the di…
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Novel Insights Into Multiple Myeloma Progression https://t.co/tEIhXIfp3D #mmsm #MultipleMyeloma #hematology
-
-
Mashup Score: 7Exploring Targeted Therapies in Multiple Myeloma - 5 month(s) ago
Investigators have explored the multifaceted nature of multiple myeloma and the potential of targeted therapies to treat patients with the disease, as summarized in a recent review.
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Exploring Targeted Therapies in Multiple Myeloma https://t.co/4682Bk1i0L #mmsm #MultipleMyeloma #hematology
-
-
Mashup Score: 3
On July 30, the FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for induction and consolidation in patients with…
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
.@US_FDA Approves Daratumumab and Hyaluronidase-fihj With VRd for Multiple Myeloma https://t.co/u32komrDG1 #mmsm #MultipleMyeloma #hematology @FDAOncology
-
-
Mashup Score: 0Transplant-Eligible Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the CASSIOPEIA Trial - 7 month(s) ago
Long-term follow-up of the phase III CASSIOPEIA trial has shown improved progression-free survival with daratumumab maintenance vs observation both among newly diagnosed patients with transplant-eligi…
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Transplant-Eligible Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the CASSIOPEIA Trial https://t.co/nKHgGzx3EJ #mmsm #multiplemyeloma #hematology
-
-
Mashup Score: 3
Undetectable measurable residual disease (MRD) status at 1 year after autologous hematopoietic cell transplantation and lenalidomide maintenance therapy was associated with improved progression-free a…
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet-
Multiple Myeloma: Is MRD Status at 1 Year After Treatment Predictive of Survival? https://t.co/O1V2xzepIu #mmsm #MultipleMyeloma #hematology
-
-
Mashup Score: 1Ciltacabtagene Autoleucel and Idecabtagene Vicleucel Approved by the FDA for Pretreated Patients With Multiple Myeloma - The ASCO Post - 9 month(s) ago
On April 5, the U.S. Food and Drug Administration (FDA) approved ciltacabtagene autoleucel (Carvykti) for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide. Ciltacabtagene autoleucel is the first and only B-cell maturation antigen (BCMA)-targeted therapy approved for the second-line treatment of patients with multiple myeloma. On
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet-
Ciltacabtagene Autoleucel and Idecabtagene Vicleucel Approved by the @US_FDA for Pretreated Patients With Multiple Myeloma https://t.co/QLB6HFGE6b #mmsm #MultipleMyeloma #hematology @FDAOncology
-
-
Mashup Score: 0Novel Drug Combination in Multiple Myeloma - The ASCO Post - 10 month(s) ago
Despite recent advances in the treatment of multi ple myeloma, the disease remains incurable. The search for innovative treatment strategies is crucial, particularly in patients whose cancer has become resistant to standard care. Venetoclax—which is currently approved to treat leukemia—works by blocking the function of the BCL-2 protein. However, the drug was only found to be effective in a small proportion of patients with multiple myeloma. In the recent study, the researchers sought to identify
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet-
Novel Drug Combination in Multiple Myeloma https://t.co/p0MKS9H5hM #mmsm #MultipleMyeloma #hematology
-
Isatuximab Plus VRd Approved by @US_FDA for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma https://t.co/AxJB8bFiJ8 #mmsm #MultipleMyeloma #hematology @FDAOncology